Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Karina Jin Yoon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0830-571X; OpenAlex author ID A5078320545; NIH RePORTER profile ID 10382686. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 9)
Trials
0
Grants
2
Labs led
1
Collaborators
27
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 grant · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper, 1 grant · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 12

  1. ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment Co-author DOI 10.64898/2026.01.15.699725↗
  2. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Co-author DOI 10.1016/j.xcrm.2024.101881↗
  3. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-025-02288-9↗
  4. The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models. Last author DOI 10.20517/cdr.2024.53↗
  5. The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells. Last author DOI 10.3389/fonc.2022.925718↗
  6. The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Last author DOI 10.3390/cancers13143470↗
  7. Developing effective combination therapy for pancreatic cancer: An overview. Last author DOI 10.1016/j.phrs.2020.104740↗
  8. Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma. Last author DOI 10.20517/cdr.2020.35↗
  9. Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. Last author DOI 10.3390/cancers12051327↗
  10. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. Last author DOI 10.1016/j.ebiom.2019.05.035↗
  11. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Last author DOI 10.1038/onc.2015.126↗
  12. Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pone.0078183↗

Grants 2

  1. Developing novel combination therapies for pancreatic cancer R01CA208272↗
  2. Developing Therapy for the Treatment of Cholangiocarcinoma R21CA205501↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Patrick L. Garcia · 9 shared papers, 2013–2024 · strength 1.29
  2. Aubrey Lynn Miller · 8 shared papers, 2016–2024 · strength 1.25
  3. Sujith Sarvesh · 3 shared papers, 2025–2026 · strength 0.65
  4. Dhana Sekhar Reddy Bandi · 3 shared papers, 2025–2026 · strength 0.65
  5. Ganji Purnachandra Nagaraju · 3 shared papers, 2025–2026 · strength 0.65
  6. Jeremy B. Foote · 3 shared papers, 2025–2026 · strength 0.65
  7. Mehmet Akce · 3 shared papers, 2025–2026 · strength 0.65
  8. Bassel F. El‐Rayes · 3 shared papers, 2025–2026 · strength 0.65
  9. Ashiq Masood · 2 shared papers, 2025–2026 · strength 0.46
  10. Robert C.A.M. van Waardenburg · 3 shared papers, 2019–2022 · strength 0.42
  11. Upender Manne · 2 shared papers, 2025 · strength 0.38
  12. Julienne L. Carstens · 2 shared papers, 2025 · strength 0.38
  13. Harrison Kim · 1 shared paper, 2026 · strength 0.27
  14. Midhun Malla · 1 shared paper, 2026 · strength 0.27
  15. Zhi-Ren Liu · 1 shared paper, 2026 · strength 0.27
  16. Yuvasri Golivi · 1 shared paper, 2025 · strength 0.19
  17. Cameron J. Herting · 1 shared paper, 2025 · strength 0.19
  18. Olatunji Boladale Alese · 1 shared paper, 2025 · strength 0.19
  19. Manoj Bhasin · 1 shared paper, 2025 · strength 0.19
  20. Gregory B. Lesinski · 1 shared paper, 2025 · strength 0.19
  21. Yulia Y. Maxuitenko · 1 shared paper, 2025 · strength 0.19
  22. Donald J Buchsbaum · 1 shared paper, 2025 · strength 0.19
  23. Adam B. Keeton · 1 shared paper, 2025 · strength 0.19
  24. Gary Anthony Piazza · 1 shared paper, 2025 · strength 0.19
  25. Asfar Sohail Azmi · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.